Highlights
- 1
- 2JAMA internal medicine · 2022
- 3Harm reduction journal · 2021
Publications
Funding
Active
7 grants- KPP30AI191337-01A1Columbia University-Weill Cornell Medicine CFAR (CU-WCM CFAR)National Institute of Allergy and Infectious Diseases · 2026–2031 · via Columbia University
- Co-IT32AI007613-26A1Research Training in Infectious DiseasesNational Institute of Allergy and Infectious Diseases · 2020–2030· 2 renewals
- Co-IR01AG081155-03Hormone Therapy for Peri- and Postmenopausal Women with HIV (HoT): ACTG A5424National Institute on Aging · 2025–2028 · via University of North Carolina at Chapel Hill
- MPIUM1AI068636-20ACTG Leadership and Operations Center (LOC) - CRS 7804National Institute of Allergy and Infectious Diseases · 2012–2027 · via University of North Carolina at Chapel Hill· 9 renewals
- KPUM1AI069419-15Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitNational Institute of Allergy and Infectious Diseases · 2013–2027· 2 renewals
- Sub-PIR01HL156788-05The Role of Sleep in Cardiovascular Health Among Men Living With HIVNational Heart, Lung, and Blood Institute · 2024–2027 · via Rutgers, The State University of New Jersey – New Brunswick
- Co-IUM1AI068619-19HIV Prevention Trials Network (HPTN106 FHI360 - WCM)National Institute of Allergy and Infectious Diseases · 2020–2026 · via FHI 360· 2 renewals
Completed grants (12)
- MPIR01HL149516-01A1ACTG LOC (A5415 FDG PET/CT Scans)National Heart, Lung, and Blood Institute · 2023–2024 · via University of California, Los Angeles
- MPIUG3HL164285-011/2 REPRIEVE Extension for Trial CompletionNational Heart, Lung, and Blood Institute · 2023–2024 · via The General Hospital Corporation (dba Massachusetts General Hospital)
- Sub-PIFHI 210569-01CoVPN 3001: Phase 3, SARS-CoV-2 Vaccine (Moderna TX, Inc.)National Institute of Allergy and Infectious Diseases · 2020–2023 · via FHI 360
- Sub-PI5 UM1 AI068619615CoVPN 3004: Phase 3, SARS-CoV-2 Vaccine (Novavax)National Institute of Allergy and Infectious Diseases · 2020–2023 · via FHI 360
- MPIR01AG054366-05Pitavastatin to Reduce Physical Function Impairment and FRailty in HIV (PREPARE) - A5332 substudy A5361s: 1560 B WB699National Institute on Aging · 2018–2023 · via University of California, Los Angeles
- MPIU01HL123336-01A5332: Prevention of Vascular Events in HIV - REPRIEVE & Substudy A5333s: Pitavastatin on CAD & Inflammatory BiomarkersNational Heart, Lung, and Blood Institute · 2014–2023 · via The Brigham & Women's Hospital INC
- MPIR01DK108438-05Effect of Pitavastatin on Kidney Function in HIV-infected Persons - CRS 7804 1560 B XA868National Institute of Diabetes and Digestive and Kidney Diseases · 2018–2022 · via University of California, Los Angeles
- Sub-PIR01DA041298-04Accessible Care Intervention for Engaging People who Inject Illicit Drugs (PWID) in Hepatitis C CareNational Institute on Drug Abuse · 2016–2021 · via Research Foundation of CUNY· 2 renewals
- KP5 U1O HA29291-02AIDS Education and Training Centers Program (AETC)Health Resources and Services Administration · 2015–2019 · via Columbia University
- PIBMS AI444-385Rates of Mixed Hepatitis C Infection in Active Injection Drug Users and the Impact of Low Level Mixed Infection on Treatment OutcomesBristol-Myers Squibb · 2015–2018
- PIK23AI065319-05Thrombocytopenia & HIV/HCV: Risk Factors & TreatmentNIAID · 2005–2010 · via NIH RePORTER
- MPIM01RR000047-47SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCVNCRR · 2005–2007 · via NIH RePORTER
Clinical research
Active
3 studies- PIA5432: Optimizing Implementation of Long-Acting ART and Implementation Research (LATIR) in the ACTG through Qualitative Research with A5359 Trial Participants and Study StaffNational Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2026)
- PIA5321:Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) StudyNational Institute of Allergy & Infectious Diseases · OPEN TO ACCRUAL (as of 2025)
- PIThe Role of Sleep in Cardiovascular Health Among Men Living with HIVRutgers, The State University of New Jersey · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (15)
- PINCT05551273Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2026)Hepatitis B; HIV Infections
- PINCT06694805A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)PHASE3 · VIIV Healthcare · CLOSED TO ACCRUAL (as of 2026)HIV Infections
- PIA Proposal to Cure HCV And Guide Engagement among People Living with HIV (CHANGE)Columbia University Medical Center · IRB STUDY CLOSURE (as of 2025)
- PINCT06101329A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in Cisgender Women in the United StatesPHASE2 · Gilead Sciences, Inc. · CLOSED TO ACCRUAL (as of 2025)Pre-Exposure Prophylaxis of HIV Infection
- PINCT04193189B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-BPHASE3 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2025)HIV Infection; Hepatitis B
- PINCT04840199Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical OutcomesPHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)HIV Infections; Cytomegalovirus; CMV
- PINCT04042740Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2024)Hepatitis C Infection; HIV Infection
- PINCT04611802A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)PHASE3 · Novavax, Inc · IRB STUDY CLOSURE (as of 2023)SARS-CoV Infection; Covid19
- PINCT04470427A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and OlderPHASE3 · ModernaTX · IRB STUDY CLOSURE (as of 2023)SARS-CoV-2
- PIIndividual Patient Emergency Compassionate Use with Casirivimab and ImdevimabWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2023)
- PICOVID-19 Prevention Network (CoVPN) ScreeningWeill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
- PINCT04042740Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)PHASE2 · National Institute of Allergy & Infectious Diseases · IRB STUDY CLOSURE (as of 2021)Hepatitis C Infection; HIV Infection
- PIRemdesivir (RDV; GS-5734) for the Treatment of Selected Coronavirus (CoV) InfectionGilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2021)
- PINCT04292899A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19PHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2020)COVID-19
- PINCT04292730A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care TreatmentPHASE3 · Gilead Sciences, Inc. · IRB STUDY CLOSURE (as of 2020)COVID-19
News mentions
- Awards & Honors: December 2025December 31, 2025
Awards, honors and achievements for the month of December.
- Updated Hep B Vaccine More Effective for People with HIVDecember 11, 2024
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.
- Accessible Care Key to Treating Hepatitis C in People Who Inject DrugsApril 7, 2022
Among participants who had hepatitis C and who injected drugs, those treated at a non-stigmatizing “accessible care” treatment center co-located with a syringe service program (SSP) were nearly three times more likely to be cured of the infectious disease compared with those referred out to local clinicians through patient navigation, according to a randomized clinical trial led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, NYU Grossman School of Medicine, and the CUNY Graduate School of Public Health and Health Policy.
- Mission Possible: Weill Cornell Medicine Launches an Unprecedented Research Effort in the Battle Against COVID-19March 2, 2021
Soon after the first case of COVID-19 was reported in New York City last March, a group of about 10 physician-scientists at Weill Cornell Medicine met to discuss a pressing issue: there were no known treatments for severe cases of the disease.
Show 5 more mentions
- COVID-19 Vaccines and Immunity: How Long Does it Take for the Vaccines to Provide Protection?February 11, 2021
With the COVID-19 vaccines rolling out across the country and more people getting vaccinated, many are wondering how long it takes for the vaccines to provide protection.
- Five Facts About the COVID-19 VaccineJanuary 21, 2021
The COVID-19 vaccine rollout is underway, bringing a sense of hope — as well as many questions about safety and who should get the vaccine. To help answer these questions, NewYork-Presbyterian experts address common concerns about the new Moderna and Pfizer-BioNTech COVID-19 vaccines and explain why they are safe.
- COVID-19 Vaccine: Your Top Questions AnsweredDecember 16, 2020
As the coronavirus vaccine rolls out across the country, an infectious disease expert answers questions about its safety and when it’s likely to be available to the general public.
- Dr. Kristen Marks on Science, Safety and the Timeline of a COVID-19 VaccineAugust 20, 2020
Dr. Kristen Marks, an associate professor of medicine in the Division of Infectious Diseases at Weill Cornell Medicine and associate attending physician at the medical center, leads the team conducting Moderna Therapeutics’s phase 3 COVID-19 vaccine trial at NewYork-Presbyterian/Weill Cornell Medical Center—one of dozens of medical centers around the U.S. where this still-experimental vaccine will be tested.
- Weill Cornell Medicine and NewYork-Presbyterian Conduct Clinical Trials for COVID-19 DrugsMay 8, 2020
As doctors face the novel coronavirus that causes COVID-19 with a very limited arsenal of treatments, physicians at Weill Cornell Medicine and NewYork-Presbyterian have rapidly mobilized to test candidate drugs in clinical trials.
External relationships
Other
Novo Nordisk Pharmaceuticals, Inc.